Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
REVIEW PAPER
Diabetic neuropathy
1
Department of Endocrinology and Diabetology, Provincial Specialist Hospital in Olsztyn, Poland
2
Department of Neurology, Provincial Specialist Hospital in Olsztyn, Poland
Submission date: 2013-04-04
Acceptance date: 2013-10-07
Online publication date: 2013-10-11
Publication date: 2020-04-08
Corresponding author
Wojciech Matuszewski
Department of Endocrinology and Diabetology, Provincial Specialist Hospital in Olsztyn, Żołnierska 18, 10-561 Olsztyn, Poland. Tel.: +48 503 090 192.
Department of Endocrinology and Diabetology, Provincial Specialist Hospital in Olsztyn, Żołnierska 18, 10-561 Olsztyn, Poland. Tel.: +48 503 090 192.
Pol. Ann. Med. 2013;20(2):154-159
KEYWORDS
ABSTRACT
Introduction:
Diabetes mellitus is gradually rising in global ranks of mortality and according to the World Health Organization it is estimated to occupy the seventh place by the year 2030. Diabetic neuropathy (DN) is the most common complication of diabetes and the symmetric distal polyneuropathy is its predominant form. Currently there are several clinical classifications of DN. Etiopathogenesis is presently the object of intense research and is yet to be fully comprehended.
Aim:
The purpose of this paper is to present and systematize the current state of knowledge on DN, in particular distal symmetric polyneuropathy. We hope that this would be helpful in the prevention, diagnosis and treatment of DN.
Material and methods:
It was based upon the available literature, publications and materials available in the online medical databases.
Discussion:
Prolonged exposure to hyperglycemia is recognized as the major mechanism and the risk factors include, among others, the degree of metabolic control of diabetes mellitus. Neuropathic symptoms result from the severity of nerve fiber damage. Nevertheless, in more than 50% of cases pain is the predominant symptom, which should encourage popularization of the use of quality of life questionnaires in diabetics. The primary and most important elements of causal treatment include the proper level of metabolic equalization, blood pressure normalization and cessation of stimulant use. Apparently the only drug influencing pathogenetic mechanisms is alpha-lipoic acid, efficiency of which has been confirmed in the ALLADYN and the SYDNEY trials.
Conclusions:
In light of the current state of knowledge, recommended first line medication in the treatment of pain associated with DN includes: tricyclic antidepressant, serotonin-norepinephrine reuptake inhibitor or antiepileptic drug. If monotherapy proves ineffective, adding a second drug may be considered, then adjuvant opioid and alternatively non-pharmacological treatment. In case of lack of response to treatment, stimulation of the spinal cord can be the final intervention.
Diabetes mellitus is gradually rising in global ranks of mortality and according to the World Health Organization it is estimated to occupy the seventh place by the year 2030. Diabetic neuropathy (DN) is the most common complication of diabetes and the symmetric distal polyneuropathy is its predominant form. Currently there are several clinical classifications of DN. Etiopathogenesis is presently the object of intense research and is yet to be fully comprehended.
Aim:
The purpose of this paper is to present and systematize the current state of knowledge on DN, in particular distal symmetric polyneuropathy. We hope that this would be helpful in the prevention, diagnosis and treatment of DN.
Material and methods:
It was based upon the available literature, publications and materials available in the online medical databases.
Discussion:
Prolonged exposure to hyperglycemia is recognized as the major mechanism and the risk factors include, among others, the degree of metabolic control of diabetes mellitus. Neuropathic symptoms result from the severity of nerve fiber damage. Nevertheless, in more than 50% of cases pain is the predominant symptom, which should encourage popularization of the use of quality of life questionnaires in diabetics. The primary and most important elements of causal treatment include the proper level of metabolic equalization, blood pressure normalization and cessation of stimulant use. Apparently the only drug influencing pathogenetic mechanisms is alpha-lipoic acid, efficiency of which has been confirmed in the ALLADYN and the SYDNEY trials.
Conclusions:
In light of the current state of knowledge, recommended first line medication in the treatment of pain associated with DN includes: tricyclic antidepressant, serotonin-norepinephrine reuptake inhibitor or antiepileptic drug. If monotherapy proves ineffective, adding a second drug may be considered, then adjuvant opioid and alternatively non-pharmacological treatment. In case of lack of response to treatment, stimulation of the spinal cord can be the final intervention.
CONFLICT OF INTEREST
None declared.
REFERENCES (43)
1.
Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J. 2006;8(6):378–382.
2.
Al-Ani FS, Al-Nimer MS, Ali FS. Dyslipidemia as a contri- butory factor in etiopathogenesis of diabetic neuropathy. Indian J Endocrinol Metab. 2011;15(2):112.
3.
Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24(46):10410–10415.
4.
Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15(12):1835–1843.
5.
Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care. 1988;11(7):592–597.
6.
Consensus Statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes. 1988;37(7):1000–1004.
7.
Cruzat A, Pavan-Langston D, Hamrah P. In vivo confocal microscopy of corneal nerves: analysis and clinical correlation. Sem Ophthalmol. 2010;25(5–6):171–177.
8.
Dyck PJ. Severity and staging of diabetic polyneuropathy. In: Gries FA, Cameron NE, Low DA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart: Thieme; 2003:170–175.
9.
Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ. The Rochester Diabetic Neuropathy Study. Reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42(6):1164–1170.
10.
Gordois A, Scuffham P, Shearer A, Oglerby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–1795.
11.
Gryz E, Szeremer P, Galicka-Latała D, Banach M, Szczudlik A, Sieradzki J. Metody rozpoznawania i oceny neuropatii cukrzycowej. Przegląd piśmiennictwa oraz doświadczenia własne [Methods of diagnosis and assessment of the diabetic neuropathy. Literature review and authors’ observations]. Przegl Lek. 2004;61(1):25–29 [in Polish].
12.
Hans-Wytrychowska A, Wytrychowski K, Sapilak BJ. Neuropatia cukrzycowa w praktyce lekarza rodzinnego – neuropatie somatyczne. [Diabetic neuropathy in general practice – somatic neuropathies]. Terapia. 2009;2(221):54–57 [in Polish].
13.
Kamiński M, Rucińska M. Pregabalina – nowy lek w terapii bólu neuropatycznego [Pregabalin – a new treatment for neuropathic pain]. Ból. 2006;7(3):15.
14.
Karnafel W. Obraz kliniczny neuropatii cukrzycowej układu wegetatywnego [Clinical presentation of diabetic autonomic neuropathy]. Diabetologia na co dzień. 2009;4(17):4–7 [in Polish].
15.
Kennedy WR. Opportunities afforded by the study of unmyelinated nerves in skin and other organs. Muscle Nerve. 2004;29(6):756–767.
18.
Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol. 1997;42(5):727–736.
19.
Ploghaus A, Narain C, Beckman CF, Clare S, Bantick S, Wise R, et al. Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci. 2001;21(24):9896–9903.
20.
Quattrini C, Harris ND, Malik RA, Tesfaye S. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care. 2007;30(3):655–659.
21.
Rowland LP. Neurologia Merritta, 1st Polish ed. Wrocław: Elsevier; 103–605 [in Polish].
22.
Shahidi AM, Sampson GP, Pritchard N, Edwards K, Russell A, Malik RA, et al. Exploring retinal and functional markers of diabetic neuropathy. Clin Exp Optom. 2010;93(5):309–323.
23.
Sheetz MJ, King JL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20):2579–2588.
24.
Shera AS, Jawad F, Maqsood A, Jamal S, Azfar M, Ahmed U. Prevalence of chronic complications and associated factors in type 2 diabetes. J Pak Med Assoc. 2004;54(2):54–59.
25.
Sivenius K, Pihlajamäki J, Partanen J, Nikanen L, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care. 2004;27(8):20021–22026.
26.
Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006;29(4):883–887.
27.
Sullivan KA, Feldman EL. New developments in diabetic neuropathy. Curr Opin Neurol. 2005;18(5):586–590.
28.
Szczeklik A. Choroby wewnętrzne. Stan wiedzy na rok 2010 [Internal medicine. State of knowledge in 2010]. Kraków: Medycyna Praktyczna; 2010: 1277–1278.
29.
Tahrani AA, Askwith T, Stevens MJ. Emerging drugs for diabetic neuropathy. Expert Opin Emerg Drugs. 2010;15(4):661–683.
31.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293.
32.
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirqoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350.
33.
Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638.
34.
Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348(9043):1698–1701.
35.
The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41(4):416–423.
36.
The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1995;122(8):561–568.
37.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635.
38.
Vileikyte L, Leventhal H, Gonzales JS, Peyrot M, Rubin RR, Ulbrecht JS, et al. Diabetic peripheral neuropathy and depressive symptoms. The association revisited. Diabetes Care. 2005;28(10):2378–2383.
39.
Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropaties. Diabetologia. 2000;43(8):957–973.
40.
Watkins PJ. Progression of diabetic autonomic neuropathy. Diabet Med. 1993;10(suppl 2):77S–78S.
42.
Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2013. Stanowisko Polskiego Towarzystwa Diabetologicznego [Clinical guidelines on the management of patients with diabetes 2013. Polish Diabetes Association] Diabetologia Kliniczna. 2013;2(suppl A).
43.
Zdrojewski T., Bandosz P., Szpakowski P. Ocena wybranych problemów dotyczących rozpowszechnienia i terapii nadciśnienia tętniczego w Polsce na podstawie badania NATPOL III PLUS [Evaluation of the selected issues regarding prevalence and treatment of arteria hypertension in Poland on the basis of NATPOL III PLUS study] In: Więcek A., Kokot F., eds. Postępy w nefrologii i nadciśnieniu tętniczym. vol. II. Kraków: Medycyna Praktyczna; 2003:11–15 [in Polish].
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
